↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
EQT removes QIAGEN from public markets at **14.2x EBITDA**, betting private ownership unlocks value faster than biotech recovery timeline.
$12.1 billion
take-private transaction
28% premium
to the 60-day volume-weighted average price
$10.2 billion
take-private of Dechra Pharmaceuticals in 2023 and the second-largest…
$2.1 billion
in annual revenue across sample preparation
EQT Private Equity agreed to acquire QIAGEN in a $12.1 billion take-private transaction, removing the German diagnostics and sample technology company from public markets after two decades on the NYSE. The all-cash offer values QIAGEN at $43.00 per share, a 28% premium to the 60-day volume-weighted average price. The transaction marks EQT's largest healthcare bet since its $10.2 billion take-private of Dechra Pharmaceuticals in 2023 and the second-largest life sciences LBO in the past eighteen months.
QIAGEN's board accepted the offer after a three-month process that began when EQT approached management in December. The company generates $2.1 billion in annual revenue across sample preparation, assay technologies, and bioinformatics, with 42% of sales derived from the Americas and 31% from Europe. QIAGEN's diagnostics portfolio includes workflow solutions for molecular testing, with particular strength in oncology and infectious disease panels. The business posted $287 million in adjusted EBITDA for the trailing twelve months ending September 2024, implying an EV/EBITDA multiple of 14.2x at the offer price. EQT is funding the acquisition with $4.8 billion in equity and $7.3 billion in committed debt facilities arranged by Goldman Sachs and Morgan Stanley.
The deal reflects two structural shifts in life sciences capital allocation. First, public market patience for diagnostics businesses evaporated in 2023 when COVID testing revenue collapsed and biotech funding dried up. QIAGEN's stock traded at 21x forward EBITDA in early 2021; by mid-2024 that multiple had compressed to 11x despite the company maintaining stable ex-COVID revenue growth of 6-8% annually. Second, private equity firms are accumulating sample technology and workflow assets that sit upstream of therapeutic development, betting that drug discovery spending will recover faster than public markets price in. EQT already owns life sciences software provider NAVIFY and laboratory services business Labco, creating a portfolio architecture where QIAGEN's sample prep technology feeds downstream analytics and testing services.
The transaction structure includes $1.1 billion in break fees if either party withdraws, with QIAGEN management rolling over $180 million in equity at the deal price. EQT committed to maintaining QIAGEN's Hilden headquarters and preserving the company's 5,800-person workforce through 2026. The firm expects to close in Q3 2025 subject to antitrust clearance in the U.S., EU, and China, where QIAGEN derives 18% of revenue. German takeover law requires a minimum acceptance threshold of 75% of outstanding shares; EQT has already secured commitments from shareholders representing 34% of the float.
Allocators should track three follow-on events. First, whether Thermo Fisher Scientific or Danaher launch competing bids within the 45-day German tender offer window, as both operate adjacent diagnostics franchises and have balance sheet capacity. Second, how EQT finances its remaining $3.2 billion in undrawn credit facilities—the firm has $24 billion in dry powder across its tenth flagship fund but historically prefers 60/40 debt-to-equity ratios for healthcare deals. Third, whether this transaction accelerates other take-private approaches to mid-cap life sciences tools companies trading below 12x EBITDA, including Bio-Techne, Bruker, and ICON.
QIAGEN's founders retain 8.2% of outstanding shares and have not yet disclosed whether they will tender into the offer.
Branded by POPS4 · proof in 60 seconds
For the principal
Watch for competing bids from Thermo Fisher or Danaher within 45 days; this multiple sets floor for mid-cap tools valuations.
For the operator
EQT's 60/40 leverage suggests limited downside protection; monitor covenant structures when debt terms are disclosed in proxy filing.
For the house
Huang Goodman holds Bio-Techne and Bruker; both trade 9-11x EBITDA and become more attractive take-private candidates after this close.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.